This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutAboutConjugate TechnologyPneumococcal DiseaseDosing & AdministrationDosing & AdministrationDosing, Administration & StoragePrevious pneumococcal VxClinical Trial ProgrammeClinical Evidence & SafetyClinical Trial programmeSafety ProfilePrivate Vaccination Service Private Vaccination ServiceIdentifying Those at Increased Risk of Pneumococcal PneumoniaSupport & ResourcesSupport & ResourcesVideosMaterials

Prescribing Information for APEXXNAR®▼ (pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)) can be found here and for Prevenar 13® (pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)) can be found here. Adverse event reporting information can be found at the bottom of the page
APEXXNAR Safety Profile APEXXNAR drug reactions

Tabulated adverse events from Phase 3 trials (4,263 participants who received APEXXNAR) and Prevenar 13 postmarketing experience1

*Events reported spontaneously in Prevenar 13 postmarketing experience; therefore, the frequencies could not be estimated from the available data and are considered as not known.
†Not reported in the adult Phase 3 trials of APEXXNAR; therefore, the frequency is not known.
§Event reported in clinical trials with Prevenar 13 with very common frequency (≥ 1/10).

About APEXXNAR

20-valent pneumococcal conjugate vaccine for adults that helps protect against pneumococcal disease originating from vaccine-type serotypes1,2

Back to Home →Loading

Pneumococcal Disease

Find out more about invasive and non-invasive pneumococcal infections, symptoms and statistics

 

Learn more →Loading

 Key Information on APEXXNAR

Key information about dosing, administration and storage for APEXXNAR1

 

Get the facts →Loading

References:

  1. APEXXNAR GB (Pneumococcal polysaccharide conjugate vaccine). Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/13461. Last accessed July 2022.
  2. Prevenar 13 GB (Pneumococcal polysaccharide conjugate vaccine). Summary of Product Characteristics. https://www.medicines.org.uk/emc/medicine/22689. Last accessed July 2022.
PP-PNR-GBR-0040. July 2022

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284. November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​